Mechanisms that may explain the lower responsiveness of ER-positive ovarian cancer than breast cancer to anti-estrogens include differences in 1) the expression of the subtypes of ER, 2) the expression of ER coactivators, and 3) expression patterns of ER isoforms. Here, ESR1 is linked to ovarian cancer.